← Leaderboards
Atsuko Hachiya
Emory University
$871,360
Attributed
$2,614,080
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $564.9K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,614,080 · 1
By mechanism
R01$2,614,080 · 1
Top collaborators
- Dmitry Lyumkis6 shared
- Stefan G Sarafianos6 shared
Most similar at Emory University
Same institution · by research overlap
- Stefan G Sarafianos$26,943,765
- Francis J Novembre$5,562,216
- Allison Ross Eckard$2,547,686
- Siddappa N Byrareddy$14,019,085
- Raymond F. Schinazi$18,319,973
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectFailureBindingBinding SitesActive SitesBiologicalCatalytic DomainClinical EffectClinical TrialsColoradoComplexBiochemicalCryoelectron MicroscopyData SetDeep SequencingDesignDinucleoside PhosphatesDrug ResistanceDrug TargetingEfavirenzEffective TherapyExcisionExperimental StudyFda Approved
Grant awards (6)
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$506,986
R01 · FY2023 · AI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$506,986
R01 · FY2022 · AI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$512,250
R01 · FY2021 · AI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$506,986
R01 · FY2020 · AI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$57,898
R01 · FY2020 · AI
Novel mechanism of integrase (IN) resistance to Dolutegravir through epistatic interactions between IN and the nucleocapsid and polypurine tract regions of HIV-1$522,974
R01 · FY2019 · AI